Investigator site file (ISF)
An investigator site file, or ISF, is the investigator-held collection of essential records documenting a clinical trial at a particular site. It forms the investigator’s part of the trial master file structure. Its purpose is to support evaluation of trial conduct and data quality while preserving the records for which the investigator is responsible.
Key takeaways
- The ISF is not simply a copy of the sponsor’s file.
- Keep responsibilities and record locations clear.
- Protect identifiers during access and archiving.
ISF and Sponsor Records
The Danish Medicines Agency’s filing guidance explains the investigator and sponsor parts of the trial master file. Essential records can include relevant correspondence and decisions, not only documents listed in a filing index.
| Collection | Practical focus |
|---|---|
| Investigator site file | Site-held evidence of conduct and investigator responsibilities. |
| Sponsor file | Sponsor-held evidence of management and oversight. |
| Medical records | Clinical records with their own access and retention rules. |
Why It Matters for Data Protection
Our recommended filing approach is to identify the authoritative location for each record, who may access it and whether an identifiable copy is actually needed elsewhere. Document access for monitors and inspectors without making unrestricted sharing the default. Keep an archive retrieval process and test whether electronic records remain readable after systems change.
Hypothetical example: A site prepares for closure. Its coordinator checks the index, resolves missing essential correspondence and confirms who will manage archive requests. Participant identification records are not copied into a general sponsor workspace merely to make the closure checklist appear complete.
Related reading: trial master file, clinical trial site. For practical support, see clinical trial data protection support.
Updated: 27 October 2026
For trials governed by the EU Clinical Trials Regulation, essential TMF content is generally retained for at least 25 years after trial end, subject to longer applicable requirements.
No. Patient medical-file retention depends on applicable national law.
Their holdings may overlap, but their responsibilities and necessary contents differ; avoid assuming identical copies are appropriate.
